Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Bad financial results growth rate -33.8% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (21.5%)
  • Dividend yield for the last twelve months 6.3%
  • Free cash flow yield 10.4% (LTM)
  • Share price is 1.1% higher than minimum and 44.3% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (10.5x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (+1.1%)45.2113
year average price 56.54  


year start price 66.77 2023-04-28

max close price 69.08 2023-05-11

min close price 44.70 2024-04-25

current price 44.70 2024-04-26
Common stocks: 2 111 517 922

Dividend Yield:  6.3%
FCF Yield LTM: 10.4%
EV / LTM EBITDA: 10.5x
EV / EBITDA annualized: 19.6x
Last revenue growth (y/y):  -3.5%
Last growth of EBITDA (y/y):  -64.1%
Historical revenue growth:  27.6%
Historical growth of EBITDA:  15.3%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 95 464
Net Debt ($m): 31 427
EV (Enterprise Value): 126 891
EBITDA LTM ($m): 12 133
EV / LTM EBITDA: 10.5x
Price to Book: 3.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-04-25Zacks Investment Research

Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

2024-04-25Zacks Investment Research

Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat

2024-04-25The Motley Fool

Why Bristol Myers Squibb Stock Is Sinking Today

2024-04-25InvestorPlace

Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts

2024-04-25Zacks Investment Research

Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

2024-04-25Barrons

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts

2024-04-25CNBC

Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss

2024-04-25Market Watch

Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates

2024-04-25Reuters

Bristol Myers posts quarterly loss, revenue rises 5%

2024-04-22Zacks Investment Research

Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data